Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email


Check back regularly for news, coverage, and announcements about MAVA.


NEA-Backed Epizyme Files to Raise Up to $69 Million in IPO

Epizyme, a Massachusetts-based biopharmaceutical firm backed by Chevy Chase-based New Enterprise Associates (NEA), has filed with the Securities and Exchange Commission (SEC) to raise up to $69 million in its initial public offering. Details of the offering, such as the number of shares to be sold or their expected price range, have yet to be announced. NEA owns approximately 25% of the company, which is developing personalized drugs for patients with genetically defined cancers. Epizyme plans to list its share on the Nasdaq Global Market under the symbol "EPZM."

Read More